Observation and Analysis on Clinical Effect of Systemic Treatment on Patients with Hepatitis B

Objective To discuss the clinical effect of systemic treatment on hepatitis B patients,and to provide the reference for the treatment of chronic severe hepatitis B.Methods Eighty patients with chronic severe hepatitis B were randomly divided into two groups.The control group was treated with basic medical care,while the treatment group was added telbivudine or lamivudine based on the treatment.Before and after the treatment,the clinical symptoms,survival rate,TBil(total bilirubin),PTA(the original activity of coagulation drunk),ALB(albumin) and HBV-DNA changes,and adverse reactions were observed and compared between the two groups.Result After the treatment,the survival rates of treatment group and control group were 80.0% and 60.0% respectively,and the difference was statistically significant between the two groups(P0.05).After 4～8 weeks of treatment,the levels of Tbil,ALB and PTA in treatment group were better improved than those in control group,and the difference was statistically significant(P0.05).After 4～8 weeks of treatment,the serum HBV-DNA level in treatment group kept under control,there were statistically significant differences in the serum HBV-DNA level between treatment group and control group(P0.05 or P0.01).No statistically significant difference was found in adverse reactions between the two groups(P0.05).Conclusions The systemic treatment based on lamivudine and telbivudine for treating chronic severe hepatitis B can increase the survival rate,speed up the improvement in liver function and decline of serum HBV-DNA.It is worthy of further research and promotion in clinical practice.